Epo Knockout GFP Anemic Mouse Model
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current animal models for studying erythropoietin (Epo) production and anemia are limited by embryonic lethality in Epo gene knockout mice and the need for induced anemia methods, which are labor-intensive and not suitable for large-scale research on adult Epo functions and disease mechanisms.
Innovation Solution
A transgenic mouse model is developed by introducing an Epo gene with a partial deletion of the untranslated region into Epo gene homozygous deficient mice, resulting in postnatal Epo production suppression and spontaneous anemia, allowing for the study of Epo action mechanisms and therapeutic approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Epo gene knockout mice are used to study anemia mechanisms, then the model should show complete Epo deficiency, but the mice die in the embryonic stage and cannot be used for adult research
Solution Approach 1:
The patent applies partial action by knocking out only part of the Epo gene (exons 2-4) rather than the entire gene, allowing the mice to survive past embryonic stage while still exhibiting anemia symptoms. This partial knockout creates a viable adult animal model that retains some Epo production capability, enabling long-term study of anemia mechanisms without complete gene elimination.
Solution Approach 2:
The patent changes the parameter of gene expression by using conditional knockout strategies and inducible systems to control Epo production levels. By adjusting the degree of gene knockout and using Cre-loxP system with different Cre driver lines, researchers can fine-tune Epo deficiency severity and timing, creating various anemia models with different survival characteristics and phenotypic expressions.
2Reliability
If conventional methods (blood removal or phenylhydrazine administration) are used to induce anemia, then Epo production decreases, but these methods are labor-intensive and not suitable for large-scale research
Solution Approach 1:
The patent implements self-service by creating transgenic mouse lines that autonomously produce anemia through genetic modification without requiring external induction procedures. The mice carry integrated Epo gene constructs with regulatory elements that automatically control Epo expression levels, allowing the animals to self-regulate their anemia state based on physiological cues, thereby eliminating the need for repeated blood removal or chemical administration.
Solution Approach 2:
The patent applies preliminary action by establishing the anemia-prone genetic background in mice before any experimental procedures begin. The transgenic Epo gene constructs are integrated into the germline, so that from birth the mice have altered Epo production capacity built-in, allowing researchers to start experiments immediately without time-consuming anemia induction protocols for each animal.
3Measurement precision
If Epo production is suppressed to very low levels under usual breeding environment, then Epo-producing cells cannot be identified or analyzed, but maintaining normal Epo levels prevents spontaneous anemia development
Solution Approach 1:
The patent uses color changes by incorporating GFP (green fluorescent protein) or RFP (red fluorescent protein) reporters under the control of Epo gene regulatory elements. Epo-producing cells express these fluorescent proteins, causing them to glow under appropriate wavelengths, making them easily identifiable and analyzable through fluorescence microscopy or flow cytometry without requiring anemia induction or complex staining procedures.
Solution Approach 2:
The patent introduces fluorescent reporter proteins as intermediaries between the Epo gene and detection methods. These reporters act as mediators that translate internal Epo production activity into externally observable fluorescent signals, allowing indirect but precise measurement of Epo-producing cells and their activity states without directly measuring Epo protein or requiring cell isolation and complex assays.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a model animal spontaneously developing anemia. More specifically, the invention relates to a transgenic non-human mammal spontaneously developing anemia associated with a postnatal decrease in production of erythropoietin (Epo), Epo-producing cells prepared from the transgenic non-human mammal, and a screening method using the Epo-producing cells.